Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a diagnosis of asthma and:
Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening
FEV1 ≥50% and ≤90% of predicted normal at screening
An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling a total dose of albuterol/salbutamol of 360/400 MDI
You may not be if
Smoking history of ≥ 10 years
Patients with a diagnosis of COPD
Patients who have been previously intubated for a severe asthma exacerbation/ attack
Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening
Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening
Patients who have had a respiratory tract infection within 6 weeks prior to screening
Patients with seasonal allergy whose asthma is likely to deteriorate during the study period
Patients with Type I or uncontrolled Type II diabetes mellitus
Clareo Health | Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol
